Status: Recruiting
Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
Regulatory Post-Marketing Surveillance in hidradenitis suppurativa, pediatric plaque psoriasis and JIA treated with Cosentyx®(secukinumab) in Korea
Participants needed: 76
Trial details
Age: 6-100Biological sex: AllType: ObservationalSponsor: Novartis PharmaceuticalsUpdated: Mar 5, 2026Locations: 1
Eligibility criteria
Adults 18 years of age and older with moderate to severe hidradenitis suppurativ... [+5]
Patients who are contraindicated according to national prescribing information [+1]